enGene (NASDAQ:ENGN) Trading Down 1.9%

Shares of enGene Holdings Inc. (NASDAQ:ENGN) traded down 1.9% during mid-day trading on Tuesday . The company traded as low as $17.88 and last traded at $17.90. 7,245 shares changed hands during trading, a decline of 84% from the average session volume of 44,400 shares. The stock had previously closed at $18.24.

Analysts Set New Price Targets

ENGN has been the topic of a number of research reports. Leerink Partnrs restated an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Morgan Stanley began coverage on shares of enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target on the stock. Finally, SVB Leerink initiated coverage on shares of enGene in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price objective for the company.

enGene Price Performance

The firm’s fifty day moving average price is $12.96.

Institutional Trading of enGene

Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in enGene during the 4th quarter valued at $185,000. Goldman Sachs Group Inc. purchased a new position in enGene in the 4th quarter valued at about $346,000. Royal Bank of Canada purchased a new stake in shares of enGene during the fourth quarter worth about $349,000. Vivo Capital LLC acquired a new position in shares of enGene in the fourth quarter worth about $6,264,000. Finally, Omega Fund Management LLC purchased a new position in enGene in the fourth quarter valued at about $10,441,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.